SCFAs could ameliorate the progression of hyperglycemia via a variety of mechanisms, including maintaining the integrity of the intestinal epithelial barrier (44), promoting liver glycogen metabolism (45), regulating the function of mitochondria (46), as well as promoting the release of Glucagon-like Peptide-1 (GLP-1) and peptide YY by activating GPR43 (47). This evidence concerns the gene FFAR2 and Hyperglycemia.